• Something wrong with this record ?

An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas

K. Polgarova, M. Trneny

. 2024 ; 24 (1-2) : 7-13. [pub] 20240202

Language English Country England, Great Britain

Document type Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc24007695

INTRODUCTION: Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains poor. Novel strategies mainly based on immunotherapy and targeted agents are currently being studied. Glofitamab is novel T-cell-engaging bispecific antibody possessing a 2:1 structure with bivalent CD20 binding. Its safety and efficacy in R/R B-cell non-Hodgkin lymphoma including DLBCL were evaluated in phase I-II NP30179 trial. AREAS COVERED: The article summarizes the milestones and latest reports on glofitamab development in the field of B-cell lymphoma treatment. EXPERT OPINION: Recently, phase II part of the NP30179 study and several other reports were published proving glofitamab potential in R/R DLBCL patients. Based on the published data, glofitamab was approved by regulatory authorities worldwide for the monotherapy of R/R DLBCL in conventional time-limited manner. It is readily accessible in case of rapidly progressing disease, and it compares well with other novel treatment options. Its side effects are similar to those of other T-cell-engaging agents and can be mitigated by pretreatment with obinutuzumab or step-up dosing. Its safety profile with manageable toxicities heads the clinical development toward combination strategies and its use in earlier therapeutic phases.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007695
003      
CZ-PrNML
005      
20240423160206.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/14712598.2024.2312243 $2 doi
035    __
$a (PubMed)38305755
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Polgarova, Kamila $u First Department of Internal Medicine-Hematology, General University Hospital, Prague, Czech Republic $u First Medicine, Charles University, Prague, Czech Republic
245    13
$a An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas / $c K. Polgarova, M. Trneny
520    9_
$a INTRODUCTION: Significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) is refractory or relapse (R/R) after the treatment. The prognosis of this patient cohort remains poor. Novel strategies mainly based on immunotherapy and targeted agents are currently being studied. Glofitamab is novel T-cell-engaging bispecific antibody possessing a 2:1 structure with bivalent CD20 binding. Its safety and efficacy in R/R B-cell non-Hodgkin lymphoma including DLBCL were evaluated in phase I-II NP30179 trial. AREAS COVERED: The article summarizes the milestones and latest reports on glofitamab development in the field of B-cell lymphoma treatment. EXPERT OPINION: Recently, phase II part of the NP30179 study and several other reports were published proving glofitamab potential in R/R DLBCL patients. Based on the published data, glofitamab was approved by regulatory authorities worldwide for the monotherapy of R/R DLBCL in conventional time-limited manner. It is readily accessible in case of rapidly progressing disease, and it compares well with other novel treatment options. Its side effects are similar to those of other T-cell-engaging agents and can be mitigated by pretreatment with obinutuzumab or step-up dosing. Its safety profile with manageable toxicities heads the clinical development toward combination strategies and its use in earlier therapeutic phases.
650    _2
$a lidé $7 D006801
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    12
$a difúzní velkobuněčný B-lymfom $x farmakoterapie $x patologie $7 D016403
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    12
$a protilátky bispecifické $x škodlivé účinky $7 D018033
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Trneny, Marek $u First Department of Internal Medicine-Hematology, General University Hospital, Prague, Czech Republic $u First Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00181398 $t Expert opinion on biological therapy $x 1744-7682 $g Roč. 24, č. 1-2 (2024), s. 7-13
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38305755 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160203 $b ABA008
999    __
$a ok $b bmc $g 2081592 $s 1217462
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 24 $c 1-2 $d 7-13 $e 20240202 $i 1744-7682 $m Expert opinion on biological therapy $n Expert Opin Biol Ther $x MED00181398
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options